Inhibition of Hepatitis B virus by cyclohexenone compounds from Antrodia camphorata

• US 7,411,003 B1
• Filed: 08/21/2007
• Issued: 08/12/2008
• Est. Priority Date: 07/09/2007
• Status: Active Grant

• Current Assignee: Golden Biotechnology Corporation
• Original Assignee: Golden Biotechnology Corporation
• Inventors: Wen, Wu-Che, Kuo, Mao-Tien, Liu, Sheng-Yun
• Primary Examiner(s): WITHERSPOON, SIKARL A
• Application Number:
  US11/842,795
• Time in Patent Office: 357 Days
• Field of Search: None
• US Class Current: 514/690
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07C 2601/16 the ring being unsaturated
• CPC Class Codes: C07C 403/02 having side-chains containing only carbon and hydrogen atoms

Abstract

The present invention relates to a compound of Antrodia camphorata used to inhibit HBV, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone which is isolated from Antrodia camphorata, and its use in inhibiting HBV effectively. The cyclohexenone compound according to the present invention showed cytotoxicity on HBV-secreting human hepatoma cell line HepG2 2.2.15, decreased synthesis of HBV particles, further inhibited synthesis of HbsAg and HbeAg effectively to achieve the goal of HBV inhibition.

Claims

1. A method for the treatment of HBV-induced diseases which comprises administering to a subject in need thereof an effective amount of a cyclohexenone compound of Antrodia camphorata having the following formula:

2. The method as claimed in claim 1, wherein the compound is isolated from the organic solvent extracts of Antrodia camphorata.

3. The method as claimed in claim 2, wherein the organic solvents are selected from the group consisting of alcohols, esters, alkanes, or halogenated alkanes.

4. The method as claimed in claim 3, wherein the alcohol is ethanol.

5. The method as claimed in claim 1, wherein the compound is isolated from the aqueous extracts of Antrodia camphorata.

6. The method as claimed in claim 1, wherein the compound is 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone.

7. The method as claimed in claim 1, wherein the compound inhibit HBV through decrease the synthesis of HbsAg and HbeAg.

8. The method as claimed in claim 7, wherein the preferred concentration of the compound in decreasing HbsAg is 10 μ

g/ml.

9. The method as claimed in claim 7, wherein the preferred concentration of the compound in decreasing HbeAg is 1 μ

g/ml.

10. The method as claimed in claim 6, wherein the compound inhibit HBV through decrease the synthesis of HbsAg and HbeAg.

11. The method as claimed in claim 10, wherein the preferred concentration of the compound in decreasing HbsAg is 10 μ

g/ml.

12. The method as claimed in claim 10, wherein the preferred concentration of the compound in decreasing HbeAg is 1 μ

g/ml.